Abstract 214P
Background
Translocation renal cell carcinoma (TRCC) represents 1% to 5% of all cases of renal cell carcinoma (RCC), with the highest frequency among children and young adults. Management of these tumors is ill defined. This is a retrospective analysis of treatment outcome in adult patient 18 years or above treated at our hospital between Janaury 2013 to November 2019.
Methods
Clinical and pathological data of 26 patients from a single institution diagnosed with TRCC between January 2013 and November 2019 were retrospectively reviewed. We analyzed our data of patients treated with Surgery only or who progressed after surgery and treated with systemic therapy or who upfront due to unresectable or metastatic disease treated with systemic therapy with respect to Event free survival and overall survival.
Results
Between Jan 2013 to Nov 2018, 26 adult patients were treated at our centre. Out of 26 patients 25 had radical surgery after evaluation and 1 had metastatic disease who was started on systemic therapy. Out 25 patient who were treated with radical surgery, 16 patients progressed and they were started on systemic therapy. Median EFS and median OS among overall population was 22 month and 30 month respectively. Among 16 patient who were treated with systemic therapy, median EFS to first line therapy was 8 month and to second line therapy was 2.5 month. Median OS was 17 month.
Conclusions
TFE RCC is rarely seen but carries significant risk of disease progression with potential response to targeted therapy of short duration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ajaykumar Singh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session